Market Pathways covers the people, challenges, and opportunities impacting the global medtech regulatory, reimbursement, and policy communities. We invite you to explore our coverage. Think Strategically.
Subscribe Today
A sortable and searchable running inventory of global medtech regulatory and policy official documents, including rules, guidance documents, memos, white papers, and more from national authorities, non-governmental groups, and global organizations.
In this week’s Pathways Picks: The EU updates its notified body guidance to address structured dialogue and leverage prior evidence, formalizes its “scientific advance” program, and pilots multinational study assessments; FDA postpones the only device panel on its calendar, reposts some documents, and faces more pressures to cull workforce; the UK tech assessor NICE proposes removing “cost saving” as a condition for device adoption; and updates from South Korea and Saudi Arabia.
In this week’s Pathways Picks: The EU updates its notified body guidance to address structured dialogue and leverage prior evidence, formalizes its “scientific advance” program, and pilots multinational study assessments; FDA postpones the only device panel on its calendar, reposts some documents, and faces more pressures to cull workforce; the UK tech assessor NICE proposes removing “cost saving” as a condition for device adoption; and updates from South Korea and Saudi Arabia.